Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Final patient treated in EDEMA3 study of DX-88 for HAE

Nov. 24, 2006

Byetta approved in E.U.

Nov. 22, 2006

Enrollment open in phase IIb study of QR-333 for diabetic peripheral neuropathy

Nov. 22, 2006

NeoRecormon recommended for once weekly use in solid tumor patients in E.U.

Nov. 21, 2006

Ferumoxytol meets phase III endpoints in non dialysis-dependent CKD patients

Nov. 21, 2006

Novel agents for obesity, lipoprotein disorders, etc. claimed

Nov. 21, 2006

Rimonabant reduces liver enzymes in overweight, dyslipidemic patients

Nov. 21, 2006

Recent Protemix and Dainippon Sumitomo patents describe new antidiabetic agents

Nov. 20, 2006

NorLevo begins phase I trial in Japan

Nov. 20, 2006

Studies detail potential of ruboxistaurin in diabetic cardiomyopathy

Nov. 20, 2006

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 15, 2026.
ASGCT 2026: Directed evolution in gene therapy
BioWorld
Directed evolution has become a central pillar in gene therapy. This engineering strategy enables the generation of more efficient variants of genetic editors and...
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...
Fosun secures rights to Aribio’s AR-1001 in potential $4.7B deal
BioWorld
Shanghai Fosun Pharmaceutical (Group) Co. Ltd. is paying $60 million up front for an option to secure exclusive rights to Aribio Co. Ltd.’s oral phase III-stage...
Biogen AD drug shows tau, cognition benefit, despite trial miss
BioWorld
Biogen Inc. has decided to advance diranersen (BIIB-080) into registrational trials for early Alzheimer’s disease, even though the antisense oligonucleotide...